CRISPR for Disease Modeling and Target Discovery


Cambridge Healthtech Institute 第14届
透过CRISPR的疾病模式与标靶发现
建构新工具并改善特异性与效能

第15届Discovery on Target其中一环

本会议以透过CRISPR的疾病模型与标靶发现为主题,标靶发现及功能性筛选等领域研究人员将齐聚一堂,讨论透过CRISPR疾病中的细胞途径、识别具潜力的药物疗法标靶的方法。本会议是一个能够聆听药厂、生物科技企业、大学、国立研究所专家分享的宝贵机会,其具有透过CRISPR为基础的基因剪辑技术,进行有助疾病模型、标靶识别与验证、功能性筛选、表观基因组工程等的合适细胞株、基因剔除、体内工具制作等经验。

Final Agenda


RECOMMENDED ALL ACCESS PACKAGE:

· September 25 Symposium: Targeting HBV

· September 25 Short Course: Applications of Functional Screening Using CRISPR and RNAi

· September 26-27 Conference: CRISPR for Disease Modeling and Target Discovery

· September 27-28 Conference: Target Identification Strategies

· September 27 Short Course: CRISPR-Based Gene Editing for Targeted Therapies

· September 28-29 Symposium: Tackling Rare Diseases


Tuesday, September 26

7:00 am Registration Open and Morning Coffee

CRISPR-Based Functional & Phenotypic Screens

8:00 Welcome Remarks

Tanuja Koppal, Ph.D., Conference Director, Cambridge Healthtech Institute

8:05 Chairperson's Opening Remarks

John Doench, Ph.D., Associate Director, Genetic Perturbation Platform, Broad Institute of Harvard and MIT

8:10 Pooled Screening with CRISPR-Cas9: Where Are We Now?

John Doench, Ph.D., Associate Director, Genetic Perturbation Platform, Broad Institute of Harvard and MIT

The ease of programming Cas9 with an sgRNA presents an abundance of potential target sites, but the on-target activity and off-target effects of individual sgRNAs can vary. We will discuss improved models that allow for increased on-target efficacy, metrics for understanding potential off-target sites, and how the combination of these findings can be used to design optimal libraries for genetic screens.

8:40 Large-scale CRISPR screening: Mining for the Deep

Roderick Beijersbergen, Ph.D., Group Leader, Netherlands Cancer Institute and Head, NKI Robotics and Screening Center

Large-scale CRISPR-Cas9 screening across many different cell lines provides the opportunity to identify gene-gene correlations based on similar phenotypic profiles. Such analyses identify known interactions and biological networks but also discover novel associations. In particular these interactions can be explored for novel therapeutic strategies for cancer.  The results of such efforts will be discussed.  

9:10 Development of New CRISPR/Cas9-Based Tools to Study Drug Interactions through Knockout and Directed Evolution

Michael Bassik, Ph.D., Assistant Professor, Department of Genetics, Stanford University

We have used parallel shRNA and CRISPR screening to explore the biology of essential and non-essential genes, and have identified the target and mechanism of action of a novel host-targeting antiviral drug. More recently, we have used pairwise expression of sgRNAs to identify synergistic combinations of drug targets, and adapted our screening systems for new applications in mutagenesis and directed evolution.

9:40 Grand Opening Coffee Break in the Exhibit Hall with Poster Viewing

10:25 Efficient CRISPR Screen Design and Analysis

Xiaole Shirley Liu, Ph.D., Professor, Department of Biostatistics and Computational Biology, Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute and Harvard School of Public Health

Genome-wide CRISPR-Cas9 screen has been widely used to interrogate gene functions. However, the analysis remains challenging and rules to design better libraries beg further refinement. I will discuss methods we have developed for the efficient design and analysis of CRISPR screens. I will also discuss our analysis of CRISPR screens comparing cells with and without drug treatment to understand the drug mechanism of action.

10:55 CRISPR-Cas9 Screens in Human Cells and Primary Neurons Identify Modifiers of C9orf72 Dipeptide Repeat Protein Toxicity

Aaron Gitler, Ph.D., Associate Professor, Department of Genetics, Stanford University

11:25 TECHNOLOGY PANEL DISCUSSION: Trends in CRISPR Technology and Applications

Moderator: John Doench, Ph.D., Associate Director, Genetic Perturbation Platform, Broad Institute of Harvard and MIT

Panelists: Experts from sponsor companies (Opportunity Available)

This panel will bring together 3-5 technical experts from leading technology and service companies to discuss trends and improvements in library design, assay reagents and platforms, and data analysis tools that users can expect to see soon to explore new applications.

11:55 Presentation to be Announced



12:25 pm Session Break

12:35 Luncheon Presentation: Going the Extra Mile: Advancing Screening with Lentiviral CRISPR and RNAi Libraries

Ryan Raver, Ph.D., Product Manager, Functional Genomics (RNAi), MilliporeSigma Life Science

CRISPR Cas9 nucleases have revolutionized the field of gene editing and high-throughput screens for target identification. MilliporeSigma seeks to share best approaches utilized and methods learned from our years of genome editing experience. In collaboration with the Wellcome Trust Sanger Institute, we have developed the first commercially available, genome-wide, truly arrayed guide RNA CRISPR-Cas9 lentiviral screening library. We will compare complementary screening technologies, such as RNAi, from small gene pathways to entire genomes.

1:15 Refreshment Break in the Exhibit Hall with Poster Viewing

Unraveling Disease Pathways Using CRISPR/Cas9

1:50 Chairperson's Remarks

James Inglese, Ph.D., Head, Assay Development & Screening Technologies, National Center for Advancing Translational Sciences, NIH

1:55 Pooled CRISPR-Cas9 Screens for Host Factors Modulating AAV and HSV Infection

Patrick Collins, Ph.D., Senior Scientist, Genome Analysis Unit, Amgen

Adeno-associated virus and herpes simplex virus are vectors for two approved, virus-mediated therapies. To identify host factors modulating infection by these two vectors, we performed genome-wide screens using a pooled CRISPR library in U-2 OS Cas9 stable cells. We then infected with AAV or HSV and selected for cells with altered GFP transgene expression or cells resistant to HSV-mediated lysis. We will detail our approach and compare the results of our screens to other efforts aimed at identifying host factors for these vectors.

2:25 CRISPR-Cas9 Editing of Herpes Simplex Virus Genomes during Lytic and Latent Infection

David M. Knipe, Ph.D., Higgins Professor and Interim Co-Chair, Department of Microbiology and Immunobiology, Harvard Medical School

There is a great medical need to cure latent viral infections, and CRISPR-Cas9 is a potential approach to edit and inactivate latent viral DNA genomes. We have used CRISPR-Cas9 technology to edit lytic herpes simplex virus genomes and reduce lytic infection. In addition, we have employed CRISPR-Cas9 to edit quiescent viral genomes in cell culture. Studies are underway to target latent infection in murine systems.

2:55 CRISPR/Cas9 Genome-Wide sgRNA Libraries for More Effective Genetic Screens

Paul Diehl, Ph.D., COO, Cellecta

Genome-wide loss-of-function screening is a fundamental method to identify genes responsible for driving biological processes. Complex pooled lentiviral-based libraries expressing large numbers of genetic disruptors, such as shRNAs (RNAi) or sgRNAs (CRISPR), make large-scale cell screening practical. CRISPR-based technologies offer not only an effective alternative, but distinct advantage.

3:10 Sponsored Presentation (Opportunity Available)

3:25 Refreshment Break in the Exhibit Hall with Poster Viewing and Poster Competition Winner Announced

4:05 Identification of Genetic Modifiers of Somatic CAG Instability in Huntington's Disease by in vivo CRISPR/Cas9 Genome Editing

Ricardo Mouro Pinto, Ph.D., Instructor in Neurology, Center for Genomic Medicine, Massachusetts General Hospital and Harvard Medical School

A recent study that looked at ~4050 Huntington's disease (HD) patients revealed that genes involved in various DNA repair pathways are likely modifiers of HD age of onset, further echoing the potential therapeutic impact of targeting these genes. To this end, we are using the CRISPR-Cas9 toolbox in HD mouse models, to determine if these genes are involved in the CAG repeat expansion process and whether they modify HD-related symptoms.

4:35 Application of Genome Editing to Develop HTS Assays for Rare and Neglected Disease Drug Discovery

James Inglese, Ph.D., Head, Assay Development & Screening Technologies, National Center for Advancing Translational Sciences, NIH

Dravet Syndrome is a convulsive disorder caused by heterozygous loss-of-function mutations in the voltage-gated sodium channel alpha-subunit encoded by the SCN1A gene. Here we describe a quantitative high-throughput screening (qHTS) assay engineered from the Neuro2a cell line in which one of the two SCN1A alleles has been replaced by a bioluminescence coincidence reporter using CRISPR/Cas9-medieated homologous recombination. Characterization of the assay and preliminary small molecule screening results will be presented.

5:05 Interactive Breakout Discussion Groups

Join a breakout discussion group. These are informal, moderated discussions with brainstorming and interactive problem solving, allowing participants from diverse backgrounds to exchange ideas and experiences and develop future collaborations around a focused topic. Details on the topics and moderators are available on the conference website.

6:05 Welcome Reception in the Exhibit Hall (Sponsorship Opportunity Available)

7:10 Close of Day

Wednesday, September 27

7:30 am Registration Open and Morning Coffee

CRISPR for Target Identification

8:00 Chairperson's Remarks

Roderick Beijersbergen, Ph.D., Group Leader, Netherlands Cancer Institute and Head, NKI Robotics and Screening Center

8:05 Validating and Invalidating Cancer Genetic Dependencies with CRISPR/Cas9

Jason Sheltzer, Ph.D., Principal Investigator, Cold Spring Harbor Laboratory

We have investigated putative genetic dependencies in triple-negative breast cancer using CRISPR/Cas9-mediated genome editing. In certain cases, on-target mutagenesis cast doubt on previously-reported cancer cell addictions. We focus on MELK and OTS167, a MELK inhibitor currently in clinical trials, and report that breast cancer cells tolerate the complete loss of MELK with no apparent fitness defect. OTS167 remains active against MELK-knockout clones, demonstrating that it necessarily kills cells through an off-target effect.

8:35 CRISPR/Cas9: A Functional Screening of the Kinome Reveals a New Potential Treatment for an Aggressive Pediatric Brain Tumor

Simone Treiger Sredni, M.D., Ph.D., Associate Professor of Pediatric Neurosurgery, Ann and Robert H. Lurie Children's Hospital of Chicago and Northwestern University, Feinberg School of Medicine

We have used a lentiviral CRISPR library to perform a systematic functional screening of the kinome by editing 160 kinases in a highly malignant pediatric brain tumor called atypical teratoid/rhabdoid tumor (AT/RT). We found that the polo-like kinase 4 (PLK-4) is essential for tumor survival, growth and migration. More importantly, we found that cells respond to PLK-4 small molecule inhibitors. This is the first time PLK-4 has been described in brain or pediatric tumors.

9:05 Sponsored Presentation (Opportunity Available)

9:35 Coffee Break in the Exhibit Hall with Poster Viewing

10:20 An IL-17 Signaling Phenotypic Screen Using the Orthogonal Methods of CRISPR and Small Molecule Libraries to Identify New Targets

Peter Slivka, Ph.D., Senior Scientist, Foundational Immunology, AbbVie Bioresearch Center

IL17 plays a critical role in the development and maintenance of autoimmune diseases including psoriasis and psoriatic arthritis. To identify novel targets in the IL17 signaling cascade, we conducted two phenotypic screens in primary keratinocytes using IL17 as a stimulus. The first screen utilized a pooled CRISPR library and the second utilized an annotated small molecule library. This talk will compare the results from the two screens and highlight a novel target of interest identified by both screens.

10:50 Nucleic Acid Detection with RNA-Guided RNA Targeting CRISPR Cas13

Jonathan Gootenberg, Ph.D. Student, Laboratory of Dr. Feng Zhang, Broad Institute of MIT and Harvard

Rapid, inexpensive, and sensitive nucleic acid detection may aid point-of-care pathogen detection, genotyping, and disease monitoring. We combine the RNA-targeting CRISPR effector Cas13a with isothermal amplification to establish a CRISPR-based diagnostic (CRISPR-Dx), providing rapid DNA or RNA detection with attomolar sensitivity and single-base mismatch specificity. We use this Cas13a-based molecular detection platform, termed SHERLOCK, to detect specific strains of Zika and Dengue virus, distinguish pathogenic bacteria, genotype human DNA, and identify cell-free tumor DNA mutations.

11:10 Harnessing RNA Targeting CRISPR Systems for Transcriptome Engineering and Human Health

Omar Abudayyeh, M.D., Ph.D. Student, Harvard-MIT Health Sciences and Technology, Laboratory of Dr. Feng Zhang, Broad Institute of MIT and Harvard

RNA plays important and diverse roles in biology, but molecular tools to manipulate and measure RNA are limited. Here, we demonstrate that RNA-targeting CRISPR effector Cas13a can be engineered for mammalian cell RNA knockdown and binding. LwCas13a can be heterologously expressed in mammalian and plant cells for targeted knockdown of either reporter or endogenous transcripts and targeted RNA binding for transcript imaging. Our results establish CRISPR-Cas13a as a flexible platform for RNA targeting with wide applicability for studying RNA in mammalian cells.

11:35 Enjoy Lunch on Your Own

12:20 pm Plenary Keynote Program

(click here for details)

2:00 Refreshment Break in the Exhibit Hall with Poster Viewing

2:45 Close of Conference

* 活动内容有可能不事先告知作更动及调整。

Choose your language
Chinese
Japanese
Korean
English

Catalog

Celebrating 25 Years

Submit A Poster

View All Sponsors

View Media Partners



免费电子邮件通知服务
免费电子邮件通知服务